High Dose Protection in High Risk Mothers

The Science

Doing What Matters, Scientifically.

High Dose Protection in High Risk Mothers

DHA Supplementation and Reduction of Early Preterm Birth Risk

DHA Dosing for Early Preterm Birth Prevention

Early preterm birth (EPB), defined as delivery before 34 weeks' gestation, is a major contributor to neonatal morbidity and mortality. Meta-analyses of omega-3 supplementation suggest that DHA reduces the risk of EPB, but the optimal dose has been uncertain. Standard prenatal vitamins typically provide 200–300 mg of DHA, yet observational studies show that pregnant people in many countries consume only ~60 mg/day. For mothers with low baseline DHA status or a history of preterm birth, higher supplementation may be needed to achieve therapeutic tissue levels.
Close-up of a bird's nest with eggs, symbolizing safety and growth

Evidence from the ADORE trial

The Assessment of DHA on Reducing Early Preterm Birth (ADORE) trial addressed this question. In this multicenter, double-blind superiority trial, 1000 mg of DHA was compared with 200 mg (the standard dose) in 1100 pregnant participants. Results showed that the higher dose group had a lower rate of early preterm birth—1.7% vs 2.4%—with a Bayesian posterior probability (pp) of 0.81 for superiority. The difference was particularly striking among women with low DHA status at enrollment: early preterm birth occurred in 2.0% of the 1000-mg group versus 4.1% of the 200-mg group. Participants assigned to 1000 mg also experienced fewer serious maternal and neonatal adverse events, including chorioamnionitis, premature rupture of membranes, feeding problems and genitourinary issues. The ObG Project summarises that the 1000-mg dose was associated with fewer EPBs and that clinicians should consider prescribing it to women with low DHA levels.

Secondary outcomes in the ADORE trial showed that 1000 mg of DHA led to longer gestation, higher birth weight and length, fewer spontaneous labors and fewer intensive-care admissions. Importantly, the higher dose conferred no advantage in women who already had high DHA status, suggesting that supplementation should be targeted.

Caring photograph of a pregnant woman's belly

Clinical guidelines for high-risk pregnancies

A 2024 clinical practice guideline summarizing evidence from randomized trials and observational studies recommends that women with low DHA intake or low blood levels consume 600–1000 mg of DHA (or DHA + EPA) per day from the second trimester until birth. These doses are considered safe—there is no evidence of increased bleeding risk or other major adverse effects at intakes up to 1000 mg/day. The FAO/WHO also allows that pregnant people may consume up to 1000 mg of DHA per day. High-dose supplementation should be considered for individuals with:

  • A previous early preterm birth or multiple pregnancies.
  • Low seafood intake (<1 serving/week) or vegetarian/vegan diets.
  • Biomarkers indicating low red-blood-cell DHA.
  • High-risk maternal conditions (e.g., gestational diabetes, obesity) where inflammation and oxidative stress are elevated.

For pregnant individuals at high risk of early preterm birth or with low DHA status, a 1000-mg DHA supplement can offer additional protection. Evidence from a large randomized trial shows that this dose lowers early preterm birth and reduces serious adverse outcomes. Clinicians should tailor dosing based on dietary intake and blood biomarkers, and high-risk mothers should use high-quality supplements under medical supervision.

back to the beginning